

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer ID6374

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
AstraZeneca (durvalumab)	All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
Black Health Agency for Equality	Board of Community Health Councils in
Cancer Black Care	Wales
Cancer 52	British National Formulary
GUTS UK	Care Quality Commission
Heartburn Cancer UK	Department of Health - Northern Ireland
Helen Rollason Cancer Charity	Healthcare Improvement Scotland
Independent Cancer Patients Voice	Medicines and Healthcare products
Macmillan Cancer Support	Regulatory Agency
Maggie's Centres	National Association of Primary Care
Marie Curie	National Pharmacy Association
Ochre	NHS Confederation
Oesophageal Patients Association	NHS Wales Joint Commissioning
OG Support	Committee
OPA Cancer Charity Oesophageal	Scottish Medicines Consortium
and Gastric Support	Welsh Government
PAWS GIST Clinic	
South Asian Health Foundation	Possible comparator companies
Specialised Healthcare Alliance	AS Kalceks (oxaliplatin)
Tenovus Cancer Care	Bristol-Myers Squibb (nivolumab)
Together Support Group	Hospira (docetaxel)
3 11 - 1	Hospira (fluorouracil)
Healthcare professional groups	Hospira (oxaliplatin)
Association of Anaesthetists	Medac (fluorouracil) Medac (fluorouracil)
Association of Cancer Physicians	Medac (leucovorin) Medac (evaliplatin)
Association of Surgeons of Great	Medac (oxaliplatin)Ranbaxy (oxaliplatin)
Britain and Ireland	Ranbaxy (oxaliplatin)Seacross Pharmaceuticals (docetaxel)
Association of Upper Gastrointestinal	 Seacross Pharmaceuticals (docetaxer) Seacross Pharmaceuticals (oxaliplatin)
Surgeons of Great Britain and Ireland	- Coacioss i Haimacoulicais (oxaliplatin)

Provisional stakeholder list for the evaluation of durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable gastric and gastro-oesophageal junction cancer ID6374




Provisional Consultees	Provisional Commentators (no right to
	submit or appeal)
 British Association of Surgical Oncology British Geriatrics Society British Institute of Radiology British Oncology Pharmacy	 Relevant research groups Cochrane Gut Group Genomics England Institute of Cancer Research MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Provisional stakeholder list for the evaluation of durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable gastric and gastrooesophageal junction cancer ID6374



Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.